

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6609)*

PROPOSED ADOPTION OF THE 2025 H SHARE INCENTIVE SCHEME

This board (the “**Board**”) of directors (the “**Directors**”) of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Board has resolved to propose the adoption of the 2025 H Share Incentive Scheme (the “**2025 H Share Incentive Scheme**”) of the Company. The 2025 H Share Incentive Scheme consists of the H share awards.

The purpose of the 2025 H Share Incentive Scheme is to:

- (i) attract and retain eligible participants whose contributions are important to the long-term growth and success of the Group, to recognize and reward eligible participants for their past contribution to the Group;
- (ii) encourage eligible participants to further contribute to the Company and work towards enhancing the value of the Company and its shares (the “**Shares**”) for the benefit of the Company and its Shareholders (the “**Shareholders**”) as a whole;
- (iii) enhance the Company’s long-term remuneration incentive strategy; and
- (iv) to align the interests of the eligible participants with those of the Company and the Shareholders to promote the long-term performance (whether in financial, business and operational aspects) of the Group.

The Board (including the independent non-executive Directors) is of the view that the adoption of the 2025 H Share Incentive Scheme will realize the aforesaid goals, and that the terms of the 2025 H Share Incentive Scheme are on normal commercial terms, fair and reasonable and in the interests of the Company and the Shareholders as a whole.

Pursuant to the articles of association of the Company, the 2025 H Share Incentive Scheme and related matters are subject to, among other things, the approval of the Shareholders at a general meeting of the Company. Pursuant to Chapter 17 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the 2025 H Share Incentive Scheme will constitute a share scheme of the Company involving the issue of new Shares or utilization of treasury shares and therefore the adoption of the 2025 H Share Incentive Scheme is subject to the approval of the Shareholders.

Operation of the 2025 H Share Incentive Scheme is therefore conditional upon the passing of the special resolution by the Shareholders at the forthcoming extraordinary general meeting of the Company (the “**EGM**”) to approve and adopt the 2025 H Share Incentive Scheme and to authorize the Board to grant award Shares to selected participants and to allot, issue and deal with the Shares which fall to be issued by the Company in respect of the award Shares granted under the 2025 H Share Incentive Scheme and the Listing Committee of the Stock Exchange granting the approval for the listing of, and permission to deal in, the H Shares which may fall to be allotted and issued in respect of the award Shares to be granted under the 2025 H Share Incentive Scheme.

The EGM will be convened to consider and, if thought fit, approve, among other things, the proposed adoption of the 2025 H Share Incentive Scheme. A circular containing, among other things, details and principal terms of the 2025 H Share Incentive Scheme together with a notice of the convening of the EGM will be published by the Company in due course in accordance with the Listing Rules.

The adoption of the 2025 H Share Incentive Scheme is subject to the approval of the Shareholders. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Wang Guohui
Chairman of the Board

Shanghai, May 7, 2025

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.